Status:

COMPLETED

T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

Lead Sponsor:

Associazione Angela Serra per la ricerca sul cancro

Collaborating Sponsors:

Fondazione Italiana Linfomi - ETS

INTERNATIONAL T-CELL NON-HODGKIN'S LYMPHOMA STUDY GROUP

Conditions:

Lymphoma, T-Cell, Peripheral

Eligibility:

All Genders

18+ years

Brief Summary

The designed study follows up the retrospective previous one by the International T-cell Non-Hodgkin's Lymphoma Study Group (International Peripheral T-Cell Lymphoma Project). It is designed as a pro...

Detailed Description

Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of neoplasms that are derived from post-thymic lymphoid cells at different stages of differentiation with different morphological pat...

Eligibility Criteria

Inclusion

  • Previously-untreated patients with de novo diagnosis of peripheral T-cell or NK/T-cell lymphoma:
  • Peripheral T-cell lymphoma unspecified;
  • Peripheral T-cell lymphoma, lymphoepithelioid variant;
  • Peripheral T-cell lymphoma, T-zone variant ;
  • Peripheral T-cell lymphoma, parafollicular variant ;
  • Angioimmunoblastic T-cell lymphoma;
  • Nasal NK/T-cell lymphoma;
  • NK/T-cell lymphoma, nasal time;
  • Anaplastic large-cell lymphoma, T/null cell, ALK+, primary systemic type
  • Anaplastic large-cell lymphoma, T/null cell, ALK-, primary systemic type
  • Anaplastic large cell lymphoma, small cell variant, ALK+
  • Anaplastic large cell lymphoma, lymphohistiocytic variant, ALK+
  • Enteropathy- type T-cell lymphoma;
  • Hepatosplenic T-cell lymphoma;
  • Peripheral gamma-delta T-cell lymphoma;
  • Subcutaneous panniculitis-like T-cell lymphoma;
  • Unclassifiable peripheral T-cell Lymphoma
  • Unclassifiable NK-cell lymphoma
  • Age over 18
  • Tissue biopsies adequate for diagnosis and classification and available for centralized review
  • Clinical data including baseline information on disease localization and laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating for at least 5 years are requested
  • Written informed consent

Exclusion

  • Age \< 18
  • Diagnosis of T-cell or NK-cell leukemia or proliferation and other than mature types including:
  • Adult T-cell leukemia/lymphoma;
  • Blastic NK-cell leukemia/lymphoma;
  • Aggressive NK-cell leukemia
  • T-cell large granular lymphocytic leukemia
  • T-cell large granular lymphocytic proliferation
  • NK-cell large granular lymphocytic proliferation
  • T-cell prolymphocytic leukemia
  • Precursor T-cell lymphoblastic leukemia/lymphoma
  • Mycosis fungoides;
  • Sézary syndrome;
  • Primary cutaneous ALCL

Key Trial Info

Start Date :

September 1 2006

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2018

Estimated Enrollment :

1650 Patients enrolled

Trial Details

Trial ID

NCT01142674

Start Date

September 1 2006

End Date

December 1 2018

Last Update

July 8 2019

Active Locations (76)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 19 (76 locations)

1

Stanford University Medical Center

Palo Alto, California, United States, 94301

2

Yale Cancer Center

New Haven, Connecticut, United States, 06510

3

St Louis Washington University

St Louis, Missouri, United States, 63130

4

University of Nebraska Medical Center

Omaha, Nebraska, United States, 68022